SAB Biotherapeutics, Inc. 8-K

What Happened

• On April 22, 2026, SAB Biotherapeutics, Inc. (SAB BIO) announced and posted a presentation and issued a press release that provide additional information and data from its Phase 1 HUMAN (first‑in‑MAN) clinical trial of SAB-142, a human anti‑thymocyte biologic. The company made the presentation available on its investor relations website and furnished the press release and presentation as Exhibits 99.1 and 99.2 to the Form 8‑K under Regulation FD disclosure.

Key Details

• Date filed: April 22, 2026.
• Program: Phase 1 HUMAN clinical trial of SAB-142 (human anti‑thymocyte biologic).
• Materials furnished as exhibits: Press Release (Exhibit 99.1) and Corporate Presentation (Exhibit 99.2).
• The presentation is available on SAB BIO’s investor website; website content is not incorporated by reference into the 8‑K. The filing includes the company’s standard forward‑looking statements disclaimer.

Why It Matters

• The release gives investors official access to new clinical data on SAB-142, which is a material development in SAB BIO’s therapeutic pipeline and may inform investor assessment of the program’s progress.
• The filing does not include financial results or regulatory decisions; it is a disclosure of clinical information and related materials. Investors should note the company’s forward‑looking statements and review SAB BIO’s risk factors in its SEC filings for context.